Search

Displaying results 161 - 170 of 6970 in total
  1. Drug

    Rituximab

    go.drugbank.com/drugs/DB00073
    ApprovedInvestigational

    FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL), and has since been approved for a variety of conditions.[L4811] On November 28, 2018, the U.S.

    Categories: Biologics for Rheumatoid Arthritis TreatmentProducts: Mabthera Concentrate for Solution for Infusion 100mg/10ml, TRUXIMA® CONCENTRATE FOR SOLUTION FOR INFUSION 10MG/ML
  2. Drug

    Gemcitabine

    go.drugbank.com/drugs/DB00441
    ApprovedInvestigational

    It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers.

    Products: GEMZAR 1gm POWDER FOR SOLUTION FOR INFUSION, GEMZAR 200mg Powder for Solution for Infusion
  3. Drug

    Von Willebrand factor human

    go.drugbank.com/drugs/DB13133
    ApprovedInvestigational

    The human von Willebrand factor (vWF) is a human plasma-derived vWF, an endogenous large multimeric plasma glycoprotein involved in hemostasis. It serves a dual role in hemostasis by mediating platelet adhesion and aggregation at the sit...

    Mixtures: Haemate P Powder and solvent for solution for injection or infusion, Haemate P 1000IU Powder and solvent for solution for injection or infusionProducts: IMMUNATE 50 IU/ML POWDER AND SOLVENT FOR SOLUTION FOR INJECTION, IMMUNATE 100 IU/ML POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
  4. Drug

    Sulfur hexafluoride

    go.drugbank.com/drugs/DB11104
    ApprovedInvestigational

    in adult patients with suboptimal echocardiograms •in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients … Sulfur hexafluoride is an ultrasound contrast agent indicated for use •in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border

    Products: SONOVUE POWDER FOR DISPERSION FOR INJECTION 8 microlitres/ml
  5. Drug

    Ferric derisomaltose

    go.drugbank.com/drugs/DB15617
    ApprovedInvestigational

    Iron deficiency is an extremely common condition and is the most frequent cause of anemia worldwide. Iron deficiency results when iron intake, iron stores, and loss of iron from the body do not adequately support production of erythrocyt...

    Products: MONOFER® SOLUTION FOR INJECTION OR INFUSION 100 MG/ML, Monofer 100 mg/ml solution for injection/infusion in vials
  6. Drug

    Toripalimab

    go.drugbank.com/drugs/DB15043
    ApprovedInvestigational

    It was first approved in China in December 2018 for the treatment of unresectable or metastatic melanoma in previously treated patients. … [A262011,A262591] Toripalimab was granted FDA approval in October 2023 for the treatment of select patients with nasopharyngeal carcinomas.[L48696]

    Categories: Programmed Death Receptor-1 Blocking AntibodyProducts: TUOYI (toripalimab) 240mg/6ml (40mg/ml) Concentrate for Solution for Infusion
  7. Drug

    Fulvestrant

    go.drugbank.com/drugs/DB00947
    ApprovedInvestigational

    While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with [alpelisib] for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative … It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.

    Categories: Estrogen Receptor Antagonists, Selective Estrogen Receptor ModulatorsProducts: FEMCORD SOLUTION FOR INJECTION 250 MG/5 ML, Faslodex Solution For Injection 250 mg/5ml
  8. Drug

    Trastuzumab deruxtecan

    go.drugbank.com/drugs/DB14962
    ApprovedInvestigational

    Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers.

    Categories: HER2 Receptor Antagonists, HER2 (Human Epidermal Growth Factor Receptor 2) inhibitorsProducts: ENHERTU POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL, Enhertu Powder For Concentrate For Solution For Infusion 100 mg/vial
  9. Drug

    Necitumumab

    go.drugbank.com/drugs/DB09559
    ApprovedInvestigationalWithdrawn

    Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). … It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression

    Categories: Epidermal Growth Factor Receptor Antagonist, EGFR (Epidermal Growth Factor Receptor) inhibitorsProducts: PORTRAZZA CONCENTRATE FOR SOLUTION FOR INFUSION 800MG/50ML
  10. Drug

    Thyrotropin alfa

    go.drugbank.com/drugs/DB00024
    ApprovedInvestigationalVet approved

    The alpha subunit of thyrotropin alfa, which is the effector region responsible for the stimulation of adenylate cyclase, displays close structural similarity with the alpha subunit of human chorionic … The beta subunit (TSHB) bestows its receptor specificity due to the uniqueness to TSH. The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone.

    Products: Thyrogen 0.9 mg Powder for Solution for Injection